How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    • Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and resource savings reasonable interpretations of the evidence?

  • Question on Consultation

    • Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Caplacizumab for treating acute acquired thrombotic thrombocytopenic purpura

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about caplacizumab

Marketing authorisation indication

2.1 Caplacizumab (Cablivi, Sanofi) has a marketing authorisation for treating adults 'experiencing an episode of acquired thrombotic thrombocytopenic purpura, in conjunction with plasma exchange and immunosuppression'. On 30 April 2020, the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending that a marketing authorisation extension is granted for caplacizumab for 'adolescents of 12 years of age and older weighing at least 40 kg'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics

Price

2.3 The list price of caplacizumab is £4,143 per 10 mg vial (excluding VAT; BNF online, May 2020). Costs may vary in different settings because of negotiated procurement discounts. The company has a commercial arrangement, which would have applied if the technology had been recommended.